JP2009519974A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519974A5
JP2009519974A5 JP2008545979A JP2008545979A JP2009519974A5 JP 2009519974 A5 JP2009519974 A5 JP 2009519974A5 JP 2008545979 A JP2008545979 A JP 2008545979A JP 2008545979 A JP2008545979 A JP 2008545979A JP 2009519974 A5 JP2009519974 A5 JP 2009519974A5
Authority
JP
Japan
Prior art keywords
compound
medicament
effective amount
aurora kinase
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062112 external-priority patent/WO2007120333A2/en
Publication of JP2009519974A publication Critical patent/JP2009519974A/ja
Publication of JP2009519974A5 publication Critical patent/JP2009519974A5/ja
Pending legal-status Critical Current

Links

JP2008545979A 2005-12-16 2006-12-14 四環系キナーゼ阻害剤 Pending JP2009519974A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75123405P 2005-12-16 2005-12-16
PCT/US2006/062112 WO2007120333A2 (en) 2005-12-16 2006-12-14 Tetracyclic kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2009519974A JP2009519974A (ja) 2009-05-21
JP2009519974A5 true JP2009519974A5 (https=) 2010-02-04

Family

ID=38610005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545979A Pending JP2009519974A (ja) 2005-12-16 2006-12-14 四環系キナーゼ阻害剤

Country Status (6)

Country Link
US (1) US20090131407A1 (https=)
EP (1) EP1968581A4 (https=)
JP (1) JP2009519974A (https=)
AU (1) AU2006342024A1 (https=)
CA (1) CA2631871A1 (https=)
WO (1) WO2007120333A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
EP2350086B1 (en) * 2008-09-23 2021-04-21 The Johns Hopkins University Fused diimidazodiazepine compounds and methods of use and manufacture thereof
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
CN106674081A (zh) * 2016-12-18 2017-05-17 南京理工大学 一种3‑甲硫基吲哚衍生物合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772325A (en) * 1972-03-24 1973-11-13 American Cyanamid Co Novel hexahydro cyclohept(b)indoles
AU762992B2 (en) * 1998-11-06 2003-07-10 Abbott Gmbh & Co. Kg Tricyclic pyrazole derivatives
EP1599202A1 (en) * 2003-02-17 2005-11-30 Pharmacia Italia S.p.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2008501628A (ja) * 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途

Similar Documents

Publication Publication Date Title
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
JP2009536652A5 (https=)
EP2018377A4 (en) 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR CONDITION IN WHICH THE INHIBITION OF HUMAN NEUTROPHILUS ELASTASE HAS A BENEFIT EFFECT
JP2009519974A5 (https=)
JP2009039101A5 (https=)
JP2009513660A5 (https=)
JP2009524695A5 (https=)
JP2009531281A5 (https=)
WO2011022440A3 (en) Heat shock protein binding compounds, compositions, and methods for making and using same
PL2029642T3 (pl) Kompozycja katalizatora do kopolimeryzacji propylenu
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
PT2359834T (pt) Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento
WO2007149797A3 (en) Use of organic compounds
IL184858A (en) Alcohol resistant dosage forms
FR2898636B1 (fr) Structure de queue-d'aronde de soufflante.
EP3276004A3 (en) Methods for treating chronic kidney disease
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
FI20065407A0 (fi) Vaikeasti väärennettävissä oleva hologrammi
EP2087890A4 (en) PREPARING WITH DELAYED RELEASE FOR TISSUE GENERATION THERAPY
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.